HLA-G molecule

Current Pharmaceutical Design

Volumn 15, Issue 28, 2009, Pages 3318-3324

  Kamishikiryo, Jun ^a   Maenaka, Katsumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

HLA G; Immune suppression; LILR; Maternal fetal interface

Indexed keywords

CD160 ANTIGEN; CYCLOSPORIN A; HLA G ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; LEUKOCYTE IMMUNOGLOBIN LIKE RECEPTOR B1; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL RECEPTOR; TACROLIMUS; UNCLASSIFIED DRUG;

BINDING SITE; CD8+ T LYMPHOCYTE; CRYSTAL STRUCTURE; CYTOTOXIC T LYMPHOCYTE; DNA POLYMORPHISM; DRUG EFFICACY; EXON; GENE EXPRESSION; GENE FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MONOCYTE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION;

ANIMALS; ANTIGENS, CD; FEMALE; FETUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POLYMORPHISM, GENETIC; PREGNANCY; RECEPTORS, ANTIGEN; RECEPTORS, IMMUNOLOGIC; RECEPTORS, KIR;

EID: 70449457506     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789105153     Document Type: Review

References (41)

1. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci USA 1987; 84: 9145-9149
2. Kuroki K, Maenaka K. Immune modulation of HLA-G dimer in maternal-fetal interface. Eur J Immunol 2007; 37: 1727-1729 (Pubitemid 47065112)
3. Hunt JS, Morales PJ, Pace JL, Fazleabas AT, Langat DK. A commentary on gestational programming and functions of HLA-G in pregnancy. Placenta 2007; 28 (Suppl A): S57-63.
4. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol 2008; 29: 125-132
5. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J 2005; 19: 681-693
6. Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, Arase H, et al. Efficient leukocyto Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 2006; 281: 10439-10447 (Pubitemid 43864583)
7. Clements CS, Kjer-Nielsen L, Kostenko L, Hoare HL, Dunstone MA, Moses E, et al. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci USA 2005; 102: 3360-3365 (Pubitemid 40328050)
8. Gonen-Gross T, Achdout H, Arnon TI, Gazit R, Stern N, Horejsi V, et al. The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecule. J Immunol 2005; 175: 4866-4874 (Pubitemid 41456368)
9. Apps R, Gardner L, Sharkey AM, Holmes N, Moffett A. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol 2007; 37: 1924-1937 (Pubitemid 47065129)
10. Morales PJ, Pace JL, Platt JS, Langat DK, Hunt JS. Synthesis of beta(2)-microglobulin-free, disulfide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells. Immunology 2007; 122: 179-188
11. Morales PJ, Pace JL, Platt JS, Phillips TA, Morgan K, Fazleabas AT, et al. Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. J Immunol 2003; 171: 6215-6224 (Pubitemid 37467245)
12. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999; 11: 603-613
13. Chapman TL, Heikema AP, West AP Jr, Bjorkman PJ. Crystal structure and ligand binding properties of the D1D2 recognition of the inhibitory receptor LIR-1(ILT2). Immunity 2000; 13: 727-736
14. Willcox BE, Thomas LM, Bjorkman PJ. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol 2003; 4: 913-919
15. Shiroishi M, Kuroki K, Rasubala L, Tsumoto K, Kumagai I, Kurimoto E, et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2(LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci USA 2006; 103: 16412-16417 (Pubitemid 44715210)
16. Shiroishi M, Kuroki K, Tsumoto K, Yokota A, Sasaki T, Amano K, et al. Entropically driven MHC class I recognition by human inhibitory receptor leukocyte Ig-like receptor B1(LILRB1/ILT2/CD85j). J Mol Biol 2006; 355: 237-248 (Pubitemid 41774128)
17. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, et al. Human inhibitory receptors Ig-like transcript 2(ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 2003; 100: 8856-8861 (Pubitemid 36899188)
18. Endo S, Sakamoto Y, Kobayashi E, Nakamura A, Takai T. Regulation of cytotoxic T lymphocyte triggering by PIR-B on dendritic cells. Proc Natl Acad Sci USA 2008; 105: 14515-14520
19. Brown D, Trowsdale J, Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 2004; 64: 215-225 (Pubitemid 39120446)
20. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen(HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999; 189: 1093-1100 (Pubitemid 29169826)
21. Kikuchi-Maki A, Catina TL, Campbell KS. Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor gamma protein. J Immunol 2005; 174: 3859-3863 (Pubitemid 40395957)
22. Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I, et al. Activation of NK cells by endocytosed receptor for soluble HLA-G. PLoS Biol 2006; 4: e9. (Pubitemid 43128319)
23. Giustiniani J, Bensussan A, Marie-Cardine A. Identification and characterization of a transmembrane isoform of CD160(CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation. J Immunol 2009; 182: 63-71.
24. Le Bouteiller P, Fons P, Herault JP, Bono F, Chabot S, Cartwright JE, et al. Soluble HLA-G and control of angiogenesis. J Reprod Immunol 2007; 76: 17-22.
25. Fons P, Chabot S, Cartwright JE, Lenfant F, L'Faqihi F, Giustiniani J, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006; 108: 2608-2615 (Pubitemid 44776995)
26. Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008; 9: 176-185
27. Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, Markel G, et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 2003; 171: 1343-1351 (Pubitemid 36900066)
28. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ. Leukocyte receptor complex-encoded immunomodulatory receptors show difering specificity for alternative HLA-B27 structures. J Immunol 2001; 167: 5543-5547 (Pubitemid 33062742)
29. Allen RL, Trowsdale J. Recognition of classical and heavy chain forms of HLA-B27 by leukocyte receptors. Curr Mol Med 2004; 4: 59-65. (Pubitemid 38279432)
30. Arosa FA, Santos SG, Powis SJ. Open conformers: the hidden face of MHC-I molecules. Trends Immunol 2007; 28: 115-123
31. Allen RL, O'Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 1999; 162: 5045-5048 (Pubitemid 29307101)
32. Bowness P. HLA B27 in health and disease: a double-edged swoed? Rheumatology (Oxford) 2002; 41: 857-868
33. Apps R, Gardner L, Moffett A. A critical look at HLA-G. Trends Immunol 2008; 29: 313-321
34. Luque J, Torres MI, Aumente MD, Marin J, Garcia-Jurado G, Gonzalez R, et al. Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy. Hum Immunol 2006; 67: 257-263 (Pubitemid 44255786)
35. Qiu J, Terasaki PI, Miller J, Mizutani K, Cai J, Carosella ED. Soluble HLA-G expression and renal graft acceptance. Am J Transplant 2006; 6: 2152-2156
36. Le Rond S, Azema C, Krawice-Radanne I, Durrbach A, Guettier C, Carosella ED, et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 2006; 176: 3266-3276 (Pubitemid 43306991)
37. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111: 4862-4870
38. Liang S, Zhang W, Horuzsko A. Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. Eur J Immunol 2006; 36: 2457-2471
39. Gueant JL, Gueant-Rodriguez RM, Gastin IA, Cornejo-Garcia JA, Viola M, Barbaud A, et al. Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity. Curr Pharm Des 2008; 14(27): 2770-2777
40. Lyn-Kew K, Standiford TJ. Immunosuppression in sepsis. Curr Pharm Des 2008; 14(19): 1870-1881
41. Mizrahi M, Ilan Y. The gut mucosa as a site for induction of regulatory T-cells. Curr Pharm Des 2009; 15(11): 1191-1202